These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30487133)

  • 1. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
    de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
    Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
    Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
    Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
    J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guanylate binding protein 5 is an immune-related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis.
    Hasegawa M; Amano Y; Kihara A; Matsubara D; Fukushima N; Takahashi H; Chikamatsu K; Nishino H; Mori Y; Yoshida N; Niki T
    Cancer Med; 2024 Jul; 13(13):e7431. PubMed ID: 38978333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
    Lin YM; Sung WW; Hsieh MJ; Tsai SC; Lai HW; Yang SM; Shen KH; Chen MK; Lee H; Yeh KT; Chen CJ
    PLoS One; 2015; 10(11):e0142656. PubMed ID: 26562534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
    Chen TC; Wu CT; Wang CP; Hsu WL; Yang TL; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2015 Nov; 51(11):1004-1010. PubMed ID: 26365985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
    Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
    Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
    Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.